Global Healthcare Opportunities’ Investment in RoslinCT

Dentons has advised RoslinC, while Slaughter and May has advised GHO on the deal.Global Healthcare Opportunities (GHO) Capital Partners executed an investment into RoslinCT, a leader in advanced cell therapies contract development and manufacturing.

Edinburgh-based RoslinCT was established in 2006 with support from Scottish Enterprise. It was formed through an initial spin-out from the Roslin Institute, which has a famous track record in genetic and cellular biology. Since 2014, the company has had a manufacturing base within the University of Edinburgh’s Centre for Regenerative Medicine. RoslinCT has worked to advance the field of regenerative medicine and is currently at the forefront of high-quality cell therapy development and manufacturing.

With the backing of GHO, a specialist investor in global healthcare, the company will significantly increase its development and manufacturing capacity, scaling the business up to build on its best-in-class therapies and better service a growing international client base.

Global Healthcare Opportunities, or GHO Capital, was founded in 2014 as a specialist healthcare investment adviser based in London. The firm was built from a shared experience and long-standing history of creating and backing businesses, accelerating growth, delivering value and championing success in the sector through prior roles with healthcare industry leader Quintiles, 3i Group, J.P. Morgan and TPG.

The Dentons team was led by Head of UK Corporate Brian Moore (Picture), supported by Senior Associate Adam Knowles, TMT Partner Ross Nicol and Tax Partner Lorna McCaa.
Involved fees earner: Adam Knowles – Dentons; Lorna McCaa – Dentons; Brian Moore – Dentons; Ross Nicol – Dentons; Law Firms: Dentons; Clients: RoslinCT;

Author: Giulia Di Palma